CZ302848B6 - Kombinace protiprujmového cinidla a derivátu epothilonu - Google Patents

Kombinace protiprujmového cinidla a derivátu epothilonu Download PDF

Info

Publication number
CZ302848B6
CZ302848B6 CZ20032529A CZ20032529A CZ302848B6 CZ 302848 B6 CZ302848 B6 CZ 302848B6 CZ 20032529 A CZ20032529 A CZ 20032529A CZ 20032529 A CZ20032529 A CZ 20032529A CZ 302848 B6 CZ302848 B6 CZ 302848B6
Authority
CZ
Czechia
Prior art keywords
group
carbon atoms
alkyl group
combination
hydrogen atom
Prior art date
Application number
CZ20032529A
Other languages
Czech (cs)
English (en)
Other versions
CZ20032529A3 (cs
Inventor
David Rothermel@John
F. Schran@Horst
Greeley@Diane
Chen@TianLing
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CZ20032529A3 publication Critical patent/CZ20032529A3/cs
Publication of CZ302848B6 publication Critical patent/CZ302848B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CZ20032529A 2001-03-19 2002-03-18 Kombinace protiprujmového cinidla a derivátu epothilonu CZ302848B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27715301P 2001-03-19 2001-03-19
US27720701P 2001-03-20 2001-03-20

Publications (2)

Publication Number Publication Date
CZ20032529A3 CZ20032529A3 (cs) 2004-09-15
CZ302848B6 true CZ302848B6 (cs) 2011-12-14

Family

ID=26958333

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032529A CZ302848B6 (cs) 2001-03-19 2002-03-18 Kombinace protiprujmového cinidla a derivátu epothilonu

Country Status (26)

Country Link
US (1) US7030147B2 (https=)
EP (1) EP1372650B1 (https=)
JP (2) JP2004519493A (https=)
KR (1) KR100863089B1 (https=)
CN (1) CN100540001C (https=)
AT (1) ATE414514T1 (https=)
AU (1) AU2002251067B2 (https=)
BR (1) BR0208142A (https=)
CA (1) CA2440111C (https=)
CY (1) CY1108845T1 (https=)
CZ (1) CZ302848B6 (https=)
DE (1) DE60229922D1 (https=)
DK (1) DK1372650T3 (https=)
ES (1) ES2318001T3 (https=)
HU (1) HUP0303621A3 (https=)
IL (1) IL157333A0 (https=)
MX (1) MXPA03008462A (https=)
NO (1) NO333106B1 (https=)
NZ (1) NZ541703A (https=)
PT (1) PT1372650E (https=)
RU (1) RU2330661C2 (https=)
SI (1) SI1372650T1 (https=)
SK (1) SK287334B6 (https=)
TW (1) TWI331525B (https=)
WO (1) WO2002074042A2 (https=)
ZA (1) ZA200306318B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
EP1312612A4 (en) * 2000-08-24 2004-09-22 Chugai Pharmaceutical Co Ltd CYCLIC PEPTIDE DERIVATIVE
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
KR20060041309A (ko) * 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) * 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
RU2253440C1 (ru) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Средство для устранения нарушений нейрогенной и эндокринной регуляции системы капиллярного кровотока
JP2008501714A (ja) * 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
PL1931350T5 (pl) * 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JP2011503075A (ja) * 2007-11-09 2011-01-27 ノバルティス アーゲー エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
KR101478925B1 (ko) * 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301831D0 (sv) * 1993-05-28 1993-05-28 Analytecon S A Pharmaceutical compositions
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
CN1122668C (zh) * 1998-12-22 2003-10-01 诺瓦提斯公司 环氧噻酮衍生物，其制备方法及其药物组合物
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
US7030147B2 (en) 2006-04-18
PT1372650E (pt) 2009-02-25
CN1622805A (zh) 2005-06-01
BR0208142A (pt) 2004-03-02
EP1372650A2 (en) 2004-01-02
CY1108845T1 (el) 2014-07-02
ATE414514T1 (de) 2008-12-15
DE60229922D1 (de) 2009-01-02
SK287334B6 (sk) 2010-07-07
JP2010006830A (ja) 2010-01-14
NO333106B1 (no) 2013-03-04
HK1061516A1 (en) 2004-09-24
HUP0303621A2 (hu) 2004-03-01
CN100540001C (zh) 2009-09-16
MXPA03008462A (es) 2003-12-08
WO2002074042A3 (en) 2003-02-27
NO20034094L (no) 2003-09-15
NZ541703A (en) 2007-04-27
IL157333A0 (en) 2004-02-19
KR100863089B1 (ko) 2008-10-13
RU2330661C2 (ru) 2008-08-10
SK11702003A3 (sk) 2004-02-03
EP1372650B1 (en) 2008-11-19
CA2440111A1 (en) 2002-09-26
AU2002251067B2 (en) 2005-05-26
TWI331525B (en) 2010-10-11
CA2440111C (en) 2010-12-07
ES2318001T3 (es) 2009-05-01
ZA200306318B (en) 2005-02-23
RU2003130058A (ru) 2005-04-10
KR20040025907A (ko) 2004-03-26
CZ20032529A3 (cs) 2004-09-15
US20040092478A1 (en) 2004-05-13
DK1372650T3 (da) 2009-03-16
SI1372650T1 (sl) 2009-04-30
HUP0303621A3 (en) 2005-03-29
WO2002074042A2 (en) 2002-09-26
PL363427A1 (en) 2004-11-15
NO20034094D0 (no) 2003-09-15
JP2004519493A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
CZ302848B6 (cs) Kombinace protiprujmového cinidla a derivátu epothilonu
AU2002251067A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20060111428A1 (en) Combination of an dpp-iv inhibitor and a ppar-alpha compound
EP0628313B1 (en) Combination of an angiotensin-II antagonising benzimidazole with manidipine for the treatment of hypertension
US20030139434A1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitor
US4804669A (en) Treatment of pain with a piperidine
TW202345798A (zh) 預防或治療肥胖的聯合療法
US7723339B2 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
HK1061516B (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
CA2519037A1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
TWI916000B (zh) 預防或治療肥胖的聯合療法
CN101612401B (zh) 包含止泻药和埃坡霉素或埃坡霉素衍生物的组合
TWI343258B (en) Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative
PL206847B1 (pl) Kombinacja zawieraj aca srodek przeciwbiegunkowy i pochodn a epotylonow a oraz zastosowanie tej kombinacji i zestaw handlowy
WO1993018769A2 (en) A new use of quinazoline derivative

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20140318